News

H3 and Foundation Medicine will continue to build upon the progress the two companies have made during the collaboration. The companies will collaborate to interrogate the FoundationCORE dataset,

Immune and Pint target closing a final agreement within 30 days. Pursuant to the anticipated final agreement, Pint will be responsible for registration of Ceplene in Latin American

Upsher-Smith’s portfolio includes around 30 pharmaceutical products, specifically intended for oral solid preparations. The acquired business will enables Sawai to develop a US business, in addition to combining R&D

Novartis has also made an undisclosed equity investment in Canada-based Parvus. Under the terms, Novartis will develop and market products made from the Navacim technology besides taking responsibility of its

Patients treated with burosumab demonstrated a statistically significant improvement in serum phosphorus levels, with 94% of patients achieving normal levels compared to 8% on placebo (p<0.0001).  Patients treated

The merger will result in a combined company with a novel protein-based discovery platform focused on inflammation and immuno-oncology. Alpine is focused on developing novel protein-based therapies using

The company presented topline results from the study of Veltassa for oral suspension on hyperkalemia when taken with or without food in patients with hyperkalemia. Veltassa is a potassium

The interim analysis was conducted after the first 20 patients enrolled into the trial had been treated for at least two months or had discontinued from the trial.

Through the collaboration, HitGen and Pfizer scientists will apply HitGen’s advanced technology platform and research capabilities in the design, synthesis, and screening of multiple proprietary DELs for Pfizer’s